BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 12712470)

  • 21. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
    Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
    Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
    Boyd J; Sonoda Y; Federici MG; Bogomolniy F; Rhei E; Maresco DL; Saigo PE; Almadrones LA; Barakat RR; Brown CL; Chi DS; Curtin JP; Poynor EA; Hoskins WJ
    JAMA; 2000 May; 283(17):2260-5. PubMed ID: 10807385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology.
    Kerner R; Sabo E; Gershoni-Baruch R; Beck D; Ben-Izhak O
    Gynecol Oncol; 2005 Nov; 99(2):367-75. PubMed ID: 16051332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients.
    Choi DH; Lee MH; Bale AE; Carter D; Haffty BG
    J Clin Oncol; 2004 May; 22(9):1638-45. PubMed ID: 15117986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
    Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
    Gynecol Oncol; 2008 Feb; 108(2):433-7. PubMed ID: 17997147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
    Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
    Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
    Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
    Spannuth WA; Thaker PH; Sood AK
    Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.
    Mahdi H; Gockley A; Esselen K; Marquard J; Nutter B; Yang B; Hinchcliff E; Horowitz N; Rose PG
    Gynecol Oncol; 2015 Dec; 139(3):407-12. PubMed ID: 26210778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
    Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Vernaglia A; Sorio R; Tumolo S; Musso P; Magni G; Pisano C; Morabito A
    Crit Rev Oncol Hematol; 2009 Sep; 71(3):233-41. PubMed ID: 19179095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers.
    Li AJ; McAllister P; Karlan BY
    Gynecol Oncol; 2010 Jan; 116(1):105-8. PubMed ID: 19818997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative CA-125 levels in patients with hereditary compared to sporadic epithelial ovarian carcinoma.
    Leitao M; Boyd J
    Gynecol Oncol; 2002 Mar; 84(3):413-5. PubMed ID: 11855879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers.
    Olawaiye A; Caesar L; Walsh D; Lyman M; Yeh J; Rodabaugh K; Marchetti D; Lele S; Odunsi K
    Gynecol Oncol; 2004 Sep; 94(3):796-802. PubMed ID: 15350375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado.
    Mullineaux LG; Castellano TM; Shaw J; Axell L; Wood ME; Diab S; Klein C; Sitarik M; Deffenbaugh AM; Graw SL
    Cancer; 2003 Aug; 98(3):597-602. PubMed ID: 12879478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor.
    Massi D; Susini T; Savino L; Boddi V; Amunni G; Colafranceschi M
    Cancer; 1996 Mar; 77(6):1131-6. PubMed ID: 8635134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma.
    Kahlenberg MS; Stoler DL; Rodriguez-Bigas MA; Weber TK; Driscoll DL; Anderson GR; Petrelli NJ
    Cancer; 2000 Apr; 88(8):1814-9. PubMed ID: 10760757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.